Skip to main content
. 2018 Sep 26;10:3911–3929. doi: 10.2147/CMAR.S169649

Table 4.

Meta-analysis results for associations of MSI/BRAF mutation status with OS in colorectal cancer

Groups N HR HRlci HRuci PHR Model I2 (%) Pheter PBegg PEgger
MSSmut/MSSwt
Overall 25 2.018 1.706 2.388 2.220E-16 R 71.3 1.681E-08 2.937E-01 3.369E-01
Cancer type
 CC 10 2.104 1.584 2.795 2.747E-07 R 77.6 6.932E-06
 MIX 17 1.913 1.561 2.344 3.850E-10 R 66.7 4.565E-05
Stage
 I–III 12 2.047 1.623 2.582 1.448E-09 R 61.9 2.352E-03
 IV 8 2.180 1.844 2.578 0.000E+00 F 0.0 4.341E-01
Therapy
 S + AC 7 2.000 1.488 2.687 4.225E-06 R 63.3 1.200E-02
 S ± AC 21 2.112 1.701 2.624 1.380E-11 R 73.5 2.391E-08
 Chemotherapy 4 1.981 1.606 2.444 9.963E-10 F 5.7% 3.640E-01
Sample size
 <500 9 2.515 1.805 3.505 5.037E-08 R 51.2% 3.713E-02
 500–1,000 8 1.856 1.415 2.432 7.464E-06 R 56.5% 2.431E-02
 >1,000 9 1.933 1.472 2.540 2.137E-06 R 82.9% 1.681E-07
Data resource
 KM 6 3.213 2.728 3.783 0.000E+00 F 20.5% 2.790E-01
 M 14 1.668 1.389 2.002 4.253E-08 R 49.2% 1.923E-02
 U 7 1.702 1.489 1.946 6.217E-15 F 15.2% 3.144E-01
MSIwt/MSSwt
Overall 17 0.996 0.801 1.24 9.761E-01 R 69.0 1.247E-05 9.045E-01 3.712E-01
Cancer type
 CC 6 0.999 0.677 1.475 9.970E-01 R 74.9 1.272E-03
 MIX 12 1.018 0.785 1.322 8.887E-01 R 65.4 8.364E-04
Stage
 I–III 6 0.912 0.589 1.412 6.818E-01 R 73.2 2.214E-03
 IV 6 1.493 1.187 1.879 6.262E-04 F 40.5 1.350E-01
Therapy
 S + AC 5 0.912 0.511 1.628 7.566E-01 R 77.5 1.369E-03
 S ± AC 11 0.979 0.763 1.255 8.650E-01 R 57.2 9.493E-03
 Chemotherapy 4 1.242 0.779 1.979 3.628E-01 R 53.3 9.246E-02
Sample size
 <500 5 1.321 0.981 1.779 6.577E-02 F 28.4 2.319E-01
 500–1,000 4 0.904 0.669 1.223 5.157E-01 F 11.5 3.353E-01
 >1,000 8 1.023 0.719 1.456 8.966E-01 R 81.4 3.425E-06
Data resource
 KM 7 1.388 1.168 1.650 1.992E-04 F 17.4 2.966E-01
 M 7 0.878 0.614 1.256 4.777E-01 R 75.2 4.737E-04
 U 4 0.742 0.546 1.008 5.613E-02 F 9.2 3.476E-01
MSImut/MSSwt
Overall 13 1.324 0.938 1.868 1.096E-01 R 88.2 2.766E-16 8.572E-01 9.922E-01
Cancer type
 CC 5 1.289 0.810 2.051 2.846E-01 R 72.8 5.389E-03
 MIX 9 1.346 0.878 2.064 1.738E-01 R 90.6 5.235E-15
Stage
 I–III 6 1.623 0.999 2.637 5.000E-02 R 74.1 1.697E-03
 IV 2 2.634 1.232 5.633 1.242E-02 R 91.8 4.909E-04
Therapy
 S + AC 3 1.669 0.919 3.031 9.296E-02 R 66.4 5.079E-02
 S ± AC 10 1.196 0.829 1.727 3.371E-01 R 80.5 5.600E-07
 Chemotherapy 1 1.800 1.371 2.362 2.235E-05
Sample size
 <500 4 2.551 1.009 6.447 4.770E-02 R 85.4 1.305E-04
 500–1,000 3 1.185 0.684 2.055 5.485E-01 R 79.9 6.874E-03
 >1,000 6 1.090 0.715 1.663 6.892E-01 R 85.1 2.782E-06
Data resource
 KM 8 1.907 1.255 2.898 2.528E-03 R 87.1 1.916E-09
 M 6 0.849 0.713 1.010 6.431E-02 F 0.0 5.365E-01
MSImut/MSIwt
Overall 22 1.470 1.243 1.740 7.122E-06 F 0.0 3.869E-01 1.010E-01 8.788E-02
Cancer type
 CC 7 1.554 1.167 2.070 2.612E-03 F 0.0 6.929E-01
 MIX 16 1.401 1.146 1.712 1.002E-03 F 9.7 3.427E-01
Stage
 I–III 8 1.599 1.217 2.101 7.517E-04 F 0.3 4.268E-01
 IV 6 1.865 1.205 2.887 5.110E-03 F 4.9 3.850E-01
Therapy
 S + AC 4 1.777 1.252 2.521 1.282E-03 F 0.0 5.766E-01
 S ± AC 16 1.439 1.165 1.779 7.517E-04 F 0.0 5.722E-01
 Chemotherapy 4 1.534 0.921 2.553 1.010E-01 F 0.0 5.241E-01
Sample size
 <500 10 2.207 1.556 3.129 8.996E-06 F 0.0 8.056E-01
 500–1,000 4 2.013 1.074 3.770 2.926E-02 F 0.0 7.291E-01
 >1,000 8 1.247 1.003 1.550 4.659E-02 F 0.0 6.770E-01
Data resource
 KM 8 1.188 0.915 1.543 1.971E-01 F 0.0 7.553E-01
 M 7 1.548 1.186 2.022 1.327E-03 F 25.6 2.330E-01
 U 8 1.844 1.303 2.611 5.606E-04 F 0.0 7.506E-01
MSIwt/MSSmut
Overall 11 0.560 0.433 0.725 1.034E-05 R 39.90 8.272E-02 5.900E-02 1.060E-01
Cancer type
 CC 5 0.511 0.390 0.670 1.174E-06 F 28.7 2.302E-01
 MIX 7 0.641 0.524 0.785 1.708E-05 F 43.60 1.002E-01
Stage
 I–III 6 0.605 0.467 0.785 1.568E-04 F 19.0 2.891E-01
 IV 3 0.640 0.510 0.805 1.281E-04 F 0.0 8.106E-01
Therapy
 S + AC 4 0.624 0.449 0.867 4.954E-03 F 0.0 6.662E-01
 S ± AC 10 0.490 0.343 0.699 8.148E-05 R 46.5 5.145E-02
 Chemotherapy 1 0.650 0.510 0.829 5.205E-04
Sample size
 <500 5 0.406 0.247 0.669 4.001E-04 F 25.0 2.551E-01
 >1,000 6 0.573 0.4 0.822 2.446E-03 R 49.40% 7.841E-02
Data resource
 KM 10 0.572 0.483 0.679 1.455E-10 F 25.70 2.072E-01
 M 2 0.635 0.184 2.185 4.715E-01 R 77.6 3.470E-02
MSImut/MSSmut
Overall 16 0.741 0.567 0.968 2.781E-02 R 48.6 1.529E-02 8.181E-01 7.608E-01
Cancer type
 CC 6 0.640 0.385 1.063 8.543E-02 R 56.1 4.400E-02
 MIX 11 0.743 0.534 1.033 7.673E-02 R 51.6 2.359E-02
Stage
 I–III 7 0.651 0.444 0.954 2.781E-02 R 48.9 6.827E-02
 IV 5 1.143 0.789 1.655 4.839E-01 F 0.0 4.886E-01
Therapy
 S + AC 4 0.918 0.656 1.284 6.171E-01 F 1.1 3.870E-01
 S ± AC 11 0.579 0.408 0.822 2.213E-03 R 53.1 1.903E-02
 Chemotherapy 4 1.054 0.676 1.645 8.181E-01 F 0.9 3.870E-01
Sample size
 <500 7 0.718 0.353 1.460 3.628E-01 R 60.5 1.883E-02
 500–1,000 2 0.825 0.420 1.620 5.755E-01 F 0.0 3.222E-01
 >1,000 8 0.677 0.503 0.912 1.017E-02 R 54.1 3.293E-02
Data resource
 KM 10 0.633 0.420 0.955 2.926E-02 R 58.2 1.057E-02
 M 3 0.635 0.399 1.012 5.613E-02 R 53.9 1.142E-01
 U 5 0.855 0.523 1.397 5.287E-01 R 53.9 6.990E-02

Note: Bold, statistically significant.

Abbreviations: AC, adjuvant chemotherapy; CC, colon cancer; M, HR was obtained from multivariate analysis; MIX, the studies included both CC and rectal cancer and results of which could not be separated; KM, HR was obtained indirectly from Kaplan–Meier plot curves; MSI, microsatellite instability; MSImut, microsatellite instability and BRAF mutation; MSIwt, microsatellite instability and BRAF wild type; MSSmut, microsatellite stable and BRAF mutation; MSSwt, microsatellite stable and BRAF wild type; RFS, recurrence free survival; S, surgery; U, HR was obtained from univariate analysis; R, random-effects model; F, fixed-effects model.